TST-003 is under clinical development by Transcenta and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase II drugs for Metastatic Colorectal Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TST-003’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TST-003 overview
TST-003 is under development for the treatment of metastatic malignant solid tumors and metastatic colorectal cancer. t is a humanized monoclonal antibody acts by targeting bone morphogenetic protein (BMP) signaling. It also acts by targeting Gremlin1. It is administered by intravenous route.
It was also under development for the treatment of esophageal cancer, pancreatic cancer, gastric cancer, lung cancer, breast cancer, prostate cancer, solid tumor, non-small cell lung cancer, esophageal squamous cell cancer and pancreatic ductal adenocarcinoma.
Transcenta overview
Transcenta (Transcenta Holding) that is a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, development and manufacturing. The company is headquartered in Suzhou, Shanghai, China.
For a complete picture of TST-003’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
